Department of Radiation Oncology, Georgetown University Hospital, Washington, DC, USA.
J Hematol Oncol. 2010 Jun 9;3:22. doi: 10.1186/1756-8722-3-22.
With conventional radiation technique alone, it is difficult to deliver radical treatment (>or= 60 Gy) to gliomas that are close to critical structures without incurring the risk of late radiation induced complications. Temozolomide-related improvements in high-grade glioma survival have placed a higher premium on optimal radiation therapy delivery. We investigated the safety and efficacy of utilizing highly conformal and precise CyberKnife radiotherapy to enhance conventional radiotherapy in the treatment of high grade glioma.
Between January 2002 and January 2009, 24 patients with good performance status and high-grade gliomas in close proximity to critical structures (i.e. eyes, optic nerves, optic chiasm and brainstem) were treated with the CyberKnife. All patients received conventional radiation therapy following tumor resection, with a median dose of 50 Gy (range: 40 - 50.4 Gy). Subsequently, an additional dose of 10 Gy was delivered in 5 successive 2 Gy daily fractions utilizing the CyberKnife image-guided radiosurgical system. The majority of patients (88%) received concurrent and/or adjuvant Temozolmide.
During CyberKnife treatments, the mean number of radiation beams utilized was 173 and the mean number of verification images was 58. Among the 24 patients, the mean clinical treatment volume was 174 cc, the mean prescription isodose line was 73% and the mean percent target coverage was 94%. At a median follow-up of 23 months for the glioblastoma multiforme cohort, the median survival was 18 months and the two-year survival rate was 37%. At a median follow-up of 63 months for the anaplastic glioma cohort, the median survival has not been reached and the 4-year survival rate was 71%. There have been no severe late complications referable to this radiation regimen in these patients.
We utilized fractionated CyberKnife radiotherapy as an adjunct to conventional radiation to improve the targeting accuracy of high-grade glioma radiation treatment. This technique was safe, effective and allowed for optimal dose-delivery in our patients. The value of image-guided radiation therapy for the treatment of high-grade gliomas deserves further study.
仅采用常规放射技术,难以在不增加迟发性放射性并发症风险的情况下,对靠近关键结构的胶质瘤给予根治性治疗(>或=60Gy)。替莫唑胺治疗高级别胶质瘤的生存率提高,对最佳放射治疗的实施提出了更高的要求。我们研究了利用高度适形和精确的 CyberKnife 放射治疗来增强常规放射治疗在高级别胶质瘤治疗中的安全性和有效性。
2002 年 1 月至 2009 年 1 月,对 24 例有良好表现状态且靠近关键结构(即眼、视神经、视交叉和脑干)的高级别胶质瘤患者采用 CyberKnife 进行治疗。所有患者在肿瘤切除后均接受常规放射治疗,中位剂量为 50Gy(范围:40-50.4Gy)。随后,利用 CyberKnife 图像引导放射外科系统,以 5 次连续每日 2Gy 剂量,额外给予 10Gy。大多数患者(88%)接受同期和/或辅助替莫唑胺治疗。
在 CyberKnife 治疗过程中,平均使用的放射线束数为 173 条,平均验证图像数为 58 张。24 例患者中,平均临床治疗体积为 174cc,平均处方等剂量线为 73%,平均目标覆盖率为 94%。在多形性胶质母细胞瘤队列的中位随访 23 个月时,中位生存期为 18 个月,两年生存率为 37%。在间变性神经胶质瘤队列的中位随访 63 个月时,中位生存期尚未达到,4 年生存率为 71%。在这些患者中,没有因这种放射方案而出现严重的迟发性并发症。
我们采用分割 CyberKnife 放射治疗作为常规放射治疗的辅助手段,以提高高级别脑肿瘤放射治疗的靶向准确性。该技术安全有效,可使我们的患者获得最佳剂量分布。图像引导放射治疗治疗高级别脑肿瘤的价值值得进一步研究。